India supplies roughly 40% of all generic drugs consumed in the United States. On Tuesday, President Trump announced a phased tariff plan targeting those imports: zero tariffs for two years, then 100%, then 200%. The stated goal is to bring drug manufacturing back to America.

The market's first reaction will be to sell Indian pharma broadly. But company filings tell a more nuanced story. Among the six most US-exposed Indian generic drug makers, exposure varies enormously — and two have already built manufacturing beachheads on American soil.

The Most Exposed: Zydus Lifesciences

Zydus Lifesciences has the most at stake. Per its FY24 annual report, the US accounted for 46% of consolidated revenues — over US$1 billion. The company distributes more than 200 generic products in America and ranks as the fifth-largest generic company in the US by prescriptions. It holds leadership positions in over 20% of its product families and ranks in the top three in approximately 60% of them.

With 402 cumulative USFDA approvals and 460 ANDA filings, Zydus has bet heavily on US generics. That bet paid off handsomely in recent years. A 200% tariff would fundamentally change the economics of nearly half the company's revenue.

Lupin and Dr. Reddy's: Big US Books, Complex Portfolios

Lupin is the third-largest generic company in the US by prescriptions. Its North America revenue reached Rs 25,155 million in Q1 FY26, growing 23% year-on-year. Roughly 35-40% of its US sales now come from complex generics — injectables, inhalation products, and biosimilars — which are harder to replicate and may face different tariff treatment than commodity generics.

Dr. Reddy's generated Rs 14,516 crore from North America in FY25, about 45% of its Global Generics segment. Its Q4 FY26 results showed North America revenue at Rs 1,756 crore, with broad-based growth moderated by lower lenalidomide sales. The company's PSAI (pharmaceutical services and active ingredients) segment — essentially a contract manufacturing business — could actually benefit if US pharma companies scramble to reshore production.

The Hedged Players: Cipla and Granules

Here is where it gets interesting for investors.

Cipla's management said it plainly at the company's July 2025 AGM: "One-third of our US production is made in the US, and that ratio is likely to increase as we launch our inhaler products." Cipla operates manufacturing facilities at Fall River, Massachusetts and Central Islip, New York. It is also investing in local MDI and DPI (inhaler) manufacturing, derisking its US respiratory franchise — which includes the number one market share in the US albuterol generics market. North America accounts for about 27% of Cipla's revenue, and a growing share of that is now tariff-proof.

Granules India has also planted its flag on US soil. Its GPI facility in Chantilly, Virginia has 1.5 billion dosages of finished dosage capacity and recently received a clean Establishment Inspection Report from the US FDA for a controlled substance ANDA. The company also operates GPAK, a packaging facility in the US with two OTC lines and one Rx line. Granules crossed Rs 53,656 million in annual revenue in FY26 — up 20% year-on-year — with growth driven primarily by formulations in North America.

Sun Pharma: The Specialty Shield

Sun Pharma, India's largest pharmaceutical company, derives about 30% of its consolidated sales from the US. But its story is different. Its Innovative Medicines portfolio — spanning dermatology, ophthalmology, and onco-dermatology — accounts for approximately 20% of company sales and is growing rapidly. These are specialty, branded products, not commodity generics, and are likely to be treated differently under any tariff regime.

Sun Pharma's own FY26 annual report noted that "generics, and in several cases, biosimilars are expected to benefit from exemptions or reduced tariff exposure to safeguard access and supply resilience." That is a bet that Washington will not actually destroy its own drug supply chain.

The Inconvenient Truth About Reshoring

That bet might be right. As Sigachi Industries noted in its FY25 annual report, India has 752 FDA-approved pharmaceutical manufacturing facilities. Transitioning that capacity to the US "could take four to five years." America cannot manufacture its own generic drugs at scale today, and tariffs do not build factories.

The two-year tariff-free window is an implicit acknowledgment of this reality. But it also creates a scramble. Companies with US manufacturing already in place — Cipla and Granules — do not need the window. Companies without it, like Zydus, face a race against a ticking clock.

What Retail Investors Should Do

Do not sell Indian pharma as a block. The tariff risk is real but unevenly distributed. Zydus Lifesciences (46% US revenue, no disclosed US manufacturing) faces the steepest challenge. Cipla (one-third of US production already domestic, expanding inhaler manufacturing) and Granules (Virginia facility operational) are structurally hedged. Sun Pharma's specialty pivot provides a different kind of insulation. For Lupin and Dr. Reddy's, watch how their complex generics and CDMO businesses evolve — these segments may be carved out from tariff schedules entirely. The two-year window means nothing needs to change in your portfolio today, but it is worth understanding which companies are building insurance and which are hoping the policy never arrives.

Data sourced from company filings on NSE via Xaro.